Medtronic Appoints Joon Lee, MD, CEO of Emory Healthcare, as New Independent Board Director

Jun 24, 2025 17:16 CST Updated 17:16

Medtronic

Medical Device Manufacturer

SIYU Annual Event Review:The First Global Ophthalmology Conference | The First Global Orthopedics Congress | The First Global Cardiovascular Conference| The First Global Medical Aesthetics Technology Conference

Coming Soon:

July 17, 2025, The 2nd Global Medical Technology Conference

September 3-5, 2025, The 3rd Global Surgical Robotics Conference

Recently，MedtronicMedtronic AnnouncesAppointment of Dr. Joon Lee as the New Independent Director of the Company's Board, effective from June 18, 2025.

# AboutDr. Joon Lee

Dr. LeeHas made significant contributions in the areas of healthcare policy, hospital operations, and innovations in doctor-patient relationships, and has participated in advisory work for the American Medical Association and other industry organizations. Currently serves asCEO of Emory HealthcareThis is Georgia's largest academic medical system, encompassing 11 hospitals, 250 medical sites, and more than 2,800 physicians. Below are the key professional milestones of Dr. Joon Lee:

Current Position

CEO of Emory Healthcare System(2021 to present): Leading the comprehensive operations of this system in the fields of medical services, research, and education, driving its excellence in cardiovascular, neuroscience, cancer treatment, and digital healthcare. Emory Healthcare SystemAnnual revenue of approximately USD 5.6 billion, and Medtronic's medical technology product lines (such asCardiac pacemakers, neuromodulation devices) Highly relevant. Responsible forIntegrate medical technology with clinical practice to advance remote monitoring, AI diagnostics, and patient experience optimization projects.。

Past Experience

Associate Professor, Department of Anesthesiology and Critical Care Medicine, Emory University School of Medicine: Before joining the administrative management position, Dr. Lee engaged in clinical and academic work, focusing on anesthesiology and critical care medicine.
Executive of University of Pittsburgh Medical Center (UPMC): Having worked at the University of Pittsburgh Medical Center (UPMC) for over 25 years, he has held several key positions, including Executive Vice President and President of Physician Services. His scope of work includes physician services, patient experience, patient access, and financial oversight of physician services.
Fellow of the American College of Cardiology and the Society for Coronary Angiography and Interventions: Obtained certification in cardiovascular disease from the American Board of Internal Medicine.
InMassachusetts General Hospital, BostonCompleted medical internship and residency, as well as two cardiology fellowships in cardiology and interventional cardiology. Additionally, he is a lecturer at Harvard Medical School.
Graduated from Dartmouth College (BA) and Duke University (MD).

Dr. Lee has a wide-ranging influence in the digital transformation of healthcare systems and cross-institutional collaboration, successfully addressing the challenges of the COVID-19 pandemic and enhancing Emory Healthcare's response capabilities to public health emergencies.

# The Significance of Joining Medtronic

Dr. Lee, as the CEO of Emory Healthcare,Bringing a Direct Healthcare Provider Perspective to Medtronic, helping the company better understand hospital procurement decisions, clinical needs, and patient experiences. His joining will promote Medtronic products (such asMicra Leadless Pacemaker, Evolut TAVR System, and Hugo Robotic-Assisted Surgery System) in hospitals, particularly in the fields of cardiovascular and neuroscience.

Company Evaluation

Medtronic Chairman and Chief Executive Officer Geoff Martha"We are very pleased to welcome Dr. Lee to the Medtronic Board of Directors. As a highly respected interventional cardiologist and healthcare executive, Dr. Lee brings deep expertise and decades of broad leadership experience in clinical research, academic leadership, and healthcare administration. He is passionate about leveraging data and technology to improve the patient and provider experience, and these insights will help us further our mission to alleviate pain, restore health, and extend the lives of patients around the world."

# About Medtronic

Medtronic(Medtronic, NYSE: MDT) was founded in 1949, with its headquarters in Minneapolis, Minnesota, USA. It is a global leading medical technology company with over 95,000 employees.

Medtronic's innovative solutions have expanded to more than 70 key disease areas, committed to providing lifelong treatment options for patients with chronic conditions. Every second, two patients worldwide benefit from Medtronic's medical technology or therapies.

Recent Developments

Diabetes Business Spin-off: In May 2025, Medtronic announced the spin-off of its diabetes business (including the MiniMed insulin pump) into an independent publicly traded company, expected to be completed by November 2026. The name of the company after the spin-off isMiniMed。
New Product Development: Invest inHugo Robotic-Assisted Surgery System and Pulse Field Ablation (PFA) Technology, used for the treatment of atrial fibrillation.
Global Expansion: Opened in Pune, IndiaGlobal Competence Center for Diabetes (GCC)), with a planned investment of 50 million US dollars, creating 600 job positions.
Board Composition: The Medtronic Board of Directors consists of 12 members, including experts from the medical, financial, and technology fields. The addition of Dr. Lee fills a gap in healthcare system management and cardiovascular expertise.

Welcome enterprises to actively participate in the conference organized by SIYU ↓

July 17, 2025, The Second Global Medical Technology Conference

September 3-5, 2025, The 3rd Global Surgical Robotics Conference